Farmas USA

Ana, me ha picado la curiosidad y he mirado tus contenidos guardados.

307!!!!! WOOOOW!!!

ARNA

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking cessation. The trial demonstrated statistically significant improvement over placebo in reducing the number of patients who smoke after 12 weeks of treatment. The detailed results of the trial are expected to be presented at a future scientific meeting.

http://boardvote.com/symbol/ARNA/communique/799937

Soy bastante desastre. Alguno me lo guardo como cosa temporal para tenerlo en cuenta y luego se quedan ahí junto con las cosas importantes.

Arena Pharmaceuticals beats by $0.07, misses on revenue • 6:56 AM

• Arena Pharmaceuticals (NASDAQ:ARNA): Q3 EPS of -$0.05 beats by $0.07.
• Revenue of $8.2M (+129.1% Y/Y) misses by $2.67M.

http://seekingalpha.com/pr/11529015-arena-pharmaceuticals-provides-corporate-update-and-reports-third-quarter-2014-financial-results?app=n

Arena product revenues up 185%

Arena Pharmaceuticals (NASDAQ:ARNA) Q3 results ($M): 

Total Revenues: 8.2 (+128%);

Product Revenues: 5.7 (+185%);

Operating Expenses: 32.5 (45%);

Net Loss: (10.7) (+38%);

Loss Per Share: (0.05) (+38%);

Quick Assets: 188.3 (-15%).

Belviq prescriptions: 143,000;

Eisai Belviq revenues: $16.8M.

ARNA

ACTC

Artículo cabrón en SA. Momento de comprar.

http://seekingalpha.com/article/2630935-time-to-sell-advanced-cell-technology-and-buy-stemcells-inc?app=1&uprof=44

Lo divertido del caso es el que precio estaba cayendo ya antes de salir el artículo y ahora parece haberse estabilizado.

El miercoles 5 al cierre tenemos la conferencia Q3. 

Promete ser interesante.

NVAX

velas 30 minutos

cierre de gap en 5,43?

NVAX

ARNA atizando tras presentar resultados, que clasico.....